S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
"The Bull Market Is Officially OVER"  (Ad)pixel
As Musk is learning, content moderation is a messy job
FDA change ushers in cheaper, easier-to-get hearing aids
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Reformers take 6 of 14 UAW board seats, could win majority
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
"The Bull Market Is Officially OVER"  (Ad)pixel
As Musk is learning, content moderation is a messy job
FDA change ushers in cheaper, easier-to-get hearing aids
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Reformers take 6 of 14 UAW board seats, could win majority
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
"The Bull Market Is Officially OVER"  (Ad)pixel
As Musk is learning, content moderation is a messy job
FDA change ushers in cheaper, easier-to-get hearing aids
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Reformers take 6 of 14 UAW board seats, could win majority
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
"The Bull Market Is Officially OVER"  (Ad)pixel
As Musk is learning, content moderation is a messy job
FDA change ushers in cheaper, easier-to-get hearing aids
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Reformers take 6 of 14 UAW board seats, could win majority
OPEC keeps oil targets amid uncertainty on Russian sanctions
NASDAQ:EVOK

Evoke Pharma - EVOK Stock Forecast, Price & News

$1.66
+0.03 (+1.83%)
(As of 12/2/2022 09:00 PM ET)
Add
Compare
Today's Range
$1.60
$1.69
50-Day Range
$1.44
$2.10
52-Week Range
$1.37
$16.80
Volume
8,900 shs
Average Volume
355,574 shs
Market Capitalization
$5.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
EVOK stock logo

About Evoke Pharma (NASDAQ:EVOK) Stock

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Receive EVOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter.

EVOK Stock News Headlines

Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com
Earnings Preview: Evoke Pharma
Evoke Pharma earnings: here's what Wall Street expects
Evoke Pharma (NASDAQ: EVOK)
EVOK Evoke Pharma, Inc.
See More Headlines
Receive EVOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter.

EVOK Company Calendar

Last Earnings
11/10/2021
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/14/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVOK
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Net Income
$-8,540,000.00
Net Margins
-391.75%
Pretax Margin
-390.45%

Debt

Sales & Book Value

Annual Sales
$1.62 million
Book Value
$1.66 per share

Miscellaneous

Free Float
3,000,000
Market Cap
$5.55 million
Optionable
Not Optionable
Beta
0.65

Key Executives

  • Mr. David A. Gonyer (Age 58)
    Co-Founder, CEO, Pres & Director
    Comp: $737.24k
  • Mr. Matthew J. D'Onofrio (Age 52)
    Co-Founder, Chief Bus. Officer, Exec. VP, Treasurer & Sec.
    Comp: $524.45k
  • Dr. Marilyn R. Carlson (Age 74)
    Chief Medical Officer
    Comp: $491.69k
  • Mr. Christopher Quesenberry
    Chief Commercial Officer - Gimoti (TM)













EVOK Stock - Frequently Asked Questions

How have EVOK shares performed in 2022?

Evoke Pharma's stock was trading at $6.60 at the start of the year. Since then, EVOK shares have decreased by 74.8% and is now trading at $1.66.
View the best growth stocks for 2022 here
.

Are investors shorting Evoke Pharma?

Evoke Pharma saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 26,400 shares, an increase of 7.8% from the October 31st total of 24,500 shares. Based on an average trading volume of 13,800 shares, the short-interest ratio is currently 1.9 days. Currently, 0.8% of the shares of the company are sold short.
View Evoke Pharma's Short Interest
.

When is Evoke Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our EVOK earnings forecast
.

How were Evoke Pharma's earnings last quarter?

Evoke Pharma, Inc. (NASDAQ:EVOK) posted its earnings results on Wednesday, November, 10th. The specialty pharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.84) by $0.12. The specialty pharmaceutical company had revenue of $0.93 million for the quarter. Evoke Pharma had a negative trailing twelve-month return on equity of 178.36% and a negative net margin of 391.75%.

When did Evoke Pharma's stock split?

Evoke Pharma shares reverse split on the morning of Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Evoke Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY).

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

How do I buy shares of Evoke Pharma?

Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evoke Pharma's stock price today?

One share of EVOK stock can currently be purchased for approximately $1.66.

How much money does Evoke Pharma make?

Evoke Pharma (NASDAQ:EVOK) has a market capitalization of $5.55 million and generates $1.62 million in revenue each year. The specialty pharmaceutical company earns $-8,540,000.00 in net income (profit) each year or ($2.7506) on an earnings per share basis.

How can I contact Evoke Pharma?

Evoke Pharma's mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The official website for the company is www.evokepharma.com. The specialty pharmaceutical company can be reached via phone at (858) 345-1494 or via email at tbui@theruthgroup.com.

This page (NASDAQ:EVOK) was last updated on 12/5/2022 by MarketBeat.com Staff